What biomarkers can distinguish Aβ-dependent versus Aβ-independent phases of tau pathology progression?

biomarker-development open composite 72%
Open a bounty challenge Fund this gap and accept submissions. SPEC-033.
Composite
72%
Novelty
80%
Mechanistic
—
Druggability
—
Priority
85%
Importance
92%
Tractability
75%
Market price
50%

Description

The debate implied therapeutic windows exist but didn’t identify how to detect transition points between Aβ-dependent and independent tau toxicity. This knowledge gap prevents patient stratification for precision medicine approaches targeting synergistic mechanisms.

Source: Debate session sess_SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974_20260416-134419 (Analysis: SDA-2026-04-16-gap-pubmed-20260410-180503-a7a03974)

Resolution criteria

Resolved when a biomarker panel distinguishes Abeta-dependent from Abeta-independent tau progression phases in longitudinal AD cohorts. Required evidence: amyloid PET, tau PET, plasma/CSF p-tau species, NfL, GFAP, and cognition modeled over time with change-point or mediation analysis. Closure requires validated thresholds that predict when tau accumulation continues despite stable/low amyloid burden, with replication in an independent cohort or trial dataset.